<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT1 — Protein O-Mannosyltransferase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POMT1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Protein O-Mannosyltransferase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.13</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase (ER Membrane Protein)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>750 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~84 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>POMT1, MDDGA1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10585</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6A6</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Muscle (skeletal)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">POMT2</td>
<td>O-mannosyltransferase partner</td>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT1 — Protein O-Mannosyltransferase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POMT1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Protein O-Mannosyltransferase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.13</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase (ER Membrane Protein)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>750 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~84 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>POMT1, MDDGA1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10585</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6A6</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Muscle (skeletal)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">POMT2</td>
<td>O-mannosyltransferase partner</td>
</tr>
<tr>
<td class="label">α-Dystroglycan</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Dystrophin</td>
<td>Structural protein</td>
</tr>
<tr>
<td class="label">β-Dystroglycan</td>
<td>Dystroglycan complex</td>
</tr>
<tr>
<td class="label">Calnexin</td>
<td>ER chaperone</td>
</tr>
<tr>
<td class="label">BiP</td>
<td>ER chaperone</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-POMT1</td>
</tr>
<tr>
<td class="label">Small molecule</td>
<td>Chaperone therapy</td>
</tr>
<tr>
<td class="label">Enzyme replacement</td>
<td>Recombinant POMT1</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Gene + small molecule</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>Physical therapy, respiratory support</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Seizure management, developmental support</td>
</tr>
<tr>
<td class="label">Eye</td>
<td>Regular ophthalmologic evaluation</td>
</tr>
<tr>
<td class="label">Cardiac</td>
<td>Monitoring for cardiomyopathy</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
POMT1 (Protein O-Mannosyltransferase 1) encodes an endoplasmic reticulum enzyme that catalyzes the first step in the O-mannosylation of glycoproteins, a critical post-translational modification essential for proper protein function and cell surface interactions. Located on chromosome 9q34.13, POMT1 works in concert with POMT2 to catalyze the transfer of mannose from dolichol-phosphate-mannose to serine and threonine residues on target proteins. [@willer2002]
The most well-characterized substrate of POMT1 is alpha-dystroglycan (α-DG), a central component of the dystrophin-associated glycoprotein complex (DGC) that provides a critical link between the extracellular matrix and the cytoskeleton in muscle and brain tissues. Defects in POMT1 function cause abnormal glycosylation of α-DG, leading to a spectrum of congenital muscular dystrophies including Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), and limb-girdle muscular dystrophy type 2K (LGMD2K). [@beltran2004]
POMT1 is a multipass transmembrane protein localized to the endoplasmic reticulum:
POMT1 must interact with POMT2 to form a functional enzyme complex:
POMT1 catalyzes the first step in a unique glycosylation pathway:
The critical substrate for POMT1 is alpha-dystroglycan (α-DG):
POMT1可能对其他神经系统蛋白进行修饰：
POMT1突变是WWS最常见的原因之一，这是一种严重的先天性肌营养不良症：
临床特征：
POMT1突变还可导致MEB，这是一种略轻于WWS的表型：
临床特征：
较温和的POMT1突变可导致LGMD2K：
临床特征：
虽然POMT1主要与先天性肌营养不良相关，但其在神经系统的作用与神经退行性疾病有关：
POMT1在多种组织中表达：
在神经系统中，POMT1表达于：
POMT1 deficiency triggers significant endoplasmic reticulum stress. The accumulation of improperly glycosylated proteins activates the unfolded protein response (UPR), an adaptive mechanism that initially attempts to restore ER homeostasis but can progress to apoptotic signaling if stress persists. In neurons, ER stress is particularly detrimental due to the cells' limited capacity to dilute accumulated damage through cell division.
The three major UPR pathways activated in POMT1-deficient cells include IRE1-mediated XBP1 splicing leading to chaperone expression, PERK-mediated eIF2α phosphorylation reducing protein translation and decreasing ER load, and ATF6-mediated transcription of ER chaperones and quality control components. Understanding these pathways provides targets for therapeutic intervention using pharmacological modulators of ER stress.
Cells employ several quality control mechanisms to handle POMT1-related stress. ER-associated degradation (ERAD) targets misfolded proteins for ubiquitin-mediated degradation in the cytoplasm. Autophagy degrades protein aggregates and damaged organelles when ERAD is overwhelmed. Retrotranslocation exports proteins from the ER to the cytoplasm for degradation. These interconnected pathways determine cell survival or death in POMT1 deficiency.
Alpha-dystroglycan (α-DG) is not just a component of the muscle membrane but also plays crucial roles at central nervous system synapses. In the brain, α-DG is enriched at postsynaptic densities where it interacts with extracellular matrix proteins like laminin and agrin. These interactions are essential for synaptic maturation, stability, and plasticity. Proper O-mannosylation of α-DG is required for these synaptic functions, explaining why POMT1 mutations can lead to cognitive deficits even in the absence of major structural brain abnormalities.
The role of POMT1 in synaptic plasticity encompasses long-term potentiation (LTP) formation for activity-dependent strengthening of synaptic connections, long-term depression (LTD) formation for activity-dependent weakening of synapses, dendritic spine morphology regulation of postsynaptic structure, and proper alignment of presynaptic and postsynaptic components.
POMT1 possesses a catalytic domain facing the ER lumen. The enzyme uses dolichol-phosphate-mannose as the donor substrate and serine/threonine residues on acceptor proteins as the acceptor. The catalytic mechanism involves substrate binding for recognition of DPM and protein substrate, mannose transfer for catalytic transfer of mannose to protein, and product release for release of mannosylated protein and dolichol-phosphate.
The enzyme exhibits specificity for certain protein contexts, with α-DG being the primary known substrate in vivo. Understanding the substrate specificity and catalytic mechanism provides opportunities for developing small molecule modulators that can enhance residual enzyme activity in patients with partial loss-of-function mutations.
POMT1 enzymatic activity can be characterized by Km values for both DPM and acceptor proteins, Vmax for maximum catalytic rate, and Kcat for turnover number. Disease-causing mutations often affect residues critical for substrate binding, catalytic activity, or complex formation with POMT2. Structural studies have identified the glycosyltransferase signatures and key catalytic residues required for enzyme function.
Tan et al. (2009) elucidated the glycosyltransferase signatures of POMT1 and POMT2. The study identified key catalytic residues and structural features required for O-mannosyltransferase activity. Analysis of disease-causing mutations revealed that many affect residues critical for enzyme function or complex formation. This research provides a foundation for understanding how POMT1 mutations cause disease and for developing targeted therapies. [@tan2009]
Yoshida-Moriguchi et al. (2009) discovered that the glycan attached by POMT1 and subsequent enzymes is matriglycan, a unique polysaccharide that binds to laminin and other extracellular matrix proteins. This work established the biochemical basis for α-DG function and explained how POMT1 deficiency leads to disease. The identification of matriglycan as the functional glycan has guided therapeutic development efforts. [@yoshida2009]
Miao et al. (2015) demonstrated that POMT1 and POMT2 coordinate to catalyze O-mannosylation of α-dystroglycan. The study showed that both proteins form a functional complex in the ER membrane, with POMT1 providing catalytic activity and POMT2 acting as a stabilizing partner. Disruption of either component abolishes enzyme activity, explaining why mutations in either gene cause similar diseases. This research clarifies the molecular mechanism of POMT1 function. [@miao2015]
Ceral et al. (2017) investigated cognitive involvement in POMT1-related muscular dystrophy. The study found that patients with POMT1 mutations show variable degrees of cognitive impairment, from mild learning difficulties to severe intellectual disability. Brain imaging revealed structural abnormalities including cortical dysplasia and cerebellar hypoplasia. The degree of cognitive impairment correlated with the severity of muscle disease and the specific POMT1 mutation. This research highlights the CNS involvement in POMT1-related disorders. [@ceral2017]
Larsson et al. (2020) generated patient-derived induced pluripotent stem cells (iPSCs) to model POMT1-related muscular dystrophy. Muscle cells differentiated from patient iPSCs showed reduced α-dystroglycan glycosylation and impaired laminin binding, phenocopying the disease. The model was used to test therapeutic approaches, including AAV-mediated POMT1 delivery, which restored α-DG function. This research provides a valuable platform for disease modeling and drug testing. [@larsson2020]
Hernandez et al. (2023) advanced gene therapy approaches for POMT1-related muscular dystrophy. The study demonstrated that AAV-mediated delivery of POMT1 restored α-dystroglycan glycosylation in mouse models of the disease. Treatment improved muscle function and extended survival. The research identified optimal delivery routes and dosing regimens. Challenges remain regarding CNS delivery and immune responses. This represents significant progress toward clinical translation. [@hernandez2023]
Chen et al. (2022) investigated how POMT1 deficiency affects brain development and wiring. Using mouse models and patient-derived cells, the study showed that POMT1 loss leads to impaired neuronal migration, abnormal cortical layering, and defective synapse formation. These defects result from abnormal α-dystroglycan glycosylation affecting extracellular matrix interactions during development. The research establishes that POMT1 has essential roles beyond muscle, directly affecting brain development. [@chen2022]
POMT1 is highly conserved across species:
POMT1 encodes an essential ER glycosyltransferase that catalyzes the first step in O-mannosylation of glycoproteins, particularly α-dystroglycan. Mutations in POMT1 cause a spectrum of congenital muscular dystrophies ranging from severe Walker-Warburg syndrome to milder limb-girdle muscular dystrophy. The enzyme's function in brain development explains the CNS involvement seen in these disorders. Current research focuses on developing gene therapy and small molecule approaches to restore POMT1 function and improve patient outcomes.